Amryt Pharma Share Chat (AMYT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Amryt Pharma	LSE:AMYT	London	Ordinary Share	GB00BDD1LS57	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	18.75p	18.50p	19.00p	18.75p	18.75p	18.75p	196,008	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	11.4	-23.2	-10.4	-	40.66

Amryt Pharma Share Discussion Threads

Showing 3251 to 3271 of 3275 messages

Chat Pages: 131 130 129 128 127 126 125 124 123 122 121 120 Older

Date	Subject	Author	Discuss
10/8/2018 23:42	Couple of AMYT charts. First one shows that the 20 day EMA has recently gone above the 50 day EMA. The first time this has happened since before last September's placing destroyed the share price See the arrows. free stock charts from uk.advfn.com The second one shows that the AMYT share price has recently broken out from a downtrend that has lasted since before Christmas when there was a recovery in the share price based on the Midas tip in the Mail. That breakout above the upper downtrend line has been retested. free stock charts from uk.advfn.com	papillon	Read Full Thread Reply
07/8/2018 12:36	Back to normal for AMYT. You can buy below the mid price so your buy will show as a sell on advfn, lse, etc.	papillon	Read Full Thread Reply
06/8/2018 14:41	I'll definitely continue to hold AMYT until the interim analysis is released in Q4 2018, bazworth. After that, who knows?	papillon	Read Full Thread Reply
04/8/2018 20:44	Best not to think about it!! It would appear that the ‘Boys and Girls’ at AMRYT at doing all that we could hope of them! V happy to hold for a good while longer!!	bazworth	Read Full Thread Reply
04/8/2018 19:08	I dread to think what the AMYT share price would be now without the Lojuxta licensing deal. Half what it is now? Definitely below 10p.	papillon	Read Full Thread Reply
03/8/2018 11:24	It's an interim analysis. That's what it says in the RNS's. From the RNS dated 19th July: "Moving to Amryt's late stage development pipeline, the investigational global Phase III ('EASE') clinical trial with AP101 for Epidermolysis bullosa ("EB") is progressing well with a pre-planned interim efficacy analysis expected to be completed in Q4 2018, and top-line data expected in Q2 2019. It is estimated that the market potential for AP101 is more than EUR1 billion." PS. It says the "interim efficacy analysis" is expected to be completed in Q4 2018. The company seem to have dropped the "early Q4"	papillon	Read Full Thread Reply
02/8/2018 22:06	Correct! I’ve been waiting bl@@dy ages!	bazworth	Read Full Thread Reply
02/8/2018 22:06	Correct! I’ve been waiting bl@@dy ages!	bazworth	Read Full Thread Reply
02/8/2018 22:04	Haha....I love that word 'whoosh'......it equates to money in the bank! 😁	greendragon777	Read Full Thread Reply
02/8/2018 21:55	Will we get an anticipatory whoosh before Nov? I reckon we will....!	bazworth	Read Full Thread Reply
02/8/2018 21:55	Will we get an anticipatory whoosh before Nov? I reckon we will....!	bazworth	Read Full Thread Reply
02/8/2018 20:54	I didn't notice that Alphabravo, I haven't been keeping an eye on the detail. However I think I recall the initial interim date of Q1 this year changed to H1 over the course of 2017 so I guess these dates tend to slip a bit over time for whatever reason. My guess is it will probably come some time in November but that's just a pure guess. The clock is ticking down fast though so it will be upon us in no time! 😃	greendragon777	Read Full Thread Reply
02/8/2018 20:38	Anyone else note how the interim readout is now "later this year" as opposed to the previous "early in Q4"?....Too much time on my hands	alphabravo321	Read Full Thread Reply
02/8/2018 18:29	Fingers crossed we'll be half way there in a couple of months time. All roads lead to AP101......😀	greendragon777	Read Full Thread Reply
02/8/2018 17:27	Yes, it will add GREATLY to the upside, waterloo, but only when AP101 receives regulatory approval for EB.	papillon	Read Full Thread Reply
02/8/2018 16:23	Yes but on approval it now has a minimum guaranteed $100m/$150m + upside.	waterloo01	Read Full Thread Reply
02/8/2018 11:03	Will the AMYT share price retest the next resistance level @ 20.3p in the next week, or so, without more good news? Got my doubts! Whilst today's news is good, as waterloo01 states, this rare desease designation is only of any value if AP101 gets approval. Everything, as before, depends on whether the EASE trial is successful, or not.	papillon	Read Full Thread Reply
02/8/2018 10:42	Have to say getting a priority review voucher is quite a coup, especially so late in the cycle. Naturally only worth something if AP101 gets approved but instantly increases it's value significantly. Added today.	waterloo01	Read Full Thread Reply
02/8/2018 07:29	Fantastic.	bermudashorts	Read Full Thread Reply
02/8/2018 07:12	Excellent news. These sell for over $150m if AP101 gets approved	waterloo01	Read Full Thread Reply
01/8/2018 12:29	Yes you could well be correct, diamondstar, on H2 2018 cash burn being lower than H1 2018. Let's hope so. You have far more insight on costs than the rest of us, diamondstar, because of your extensive biopharma experience and knowledge. IMO the most important driver of the AMYT share price will be the EASE trial results. The EASE phase III trial is why I'm invested in AMYT. EDIT: Well the Ichimoku chart has recently turned Strongly Bullish on AMYT (visit ichimokutrader.com to see their AMYT chart). It wouldn't surprise me to see the AMYT share price start to slowly rise from the current 18.375p as we get closer to the interim results (expected early September) and the EASE interim update (expected early October)	papillon	Read Full Thread Reply

Chat Pages: 131 130 129 128 127 126 125 124 123 122 121 120 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.